Graves' Disease - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Graves' Disease Emerging Therapy and TPP Insights

Thelansis's "Graves' Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Graves' Disease Overview

Graves' disease is an autoimmune disorder in which thyroid-stimulating immunoglobulins activate the TSH receptor, causing hyperthyroidism with symptoms such as weight loss, heat intolerance, palpitations, tremor, and goiter; it commonly produces thyroid eye disease (orbitopathy) and occasionally pretibial myxedema. Untreated hyperthyroidism can cause cardiac complications, bone loss, menstrual and fertility disturbances, and risks during pregnancy for both mother and fetus. Graves' disease often coexists with other autoimmune conditions (for example, type 1 diabetes, pernicious anemia, vitiligo, and rheumatoid arthritis). Diagnosis is clinical and biochemical (suppressed TSH, elevated free T4/T3) with supportive testing for TSH-receptor antibodies and thyroid imaging when indicated; treatment options include antithyroid drugs, radioactive iodine, or thyroidectomy, with specific management for orbitopathy as needed.

Key Highlights

• In France, incident Graves' disease cases are projected to increase from 34,206 in 2025 to 35,982 by 2035.
• Graves' disease is the leading cause of hyperthyroidism and disproportionately affects women.
• Disease burden is driven by recurrent hyperthyroidism and thyroid eye disease complications.
• Growing awareness and earlier diagnosis are improving disease management.

Market Overview

• The Italy Graves' disease market is projected to grow from $220.5M in 2025 to $294M by 2035.
• Market growth is supported by:
• Increasing diagnosis and treatment rates
• Adoption of therapies for thyroid eye disease
• Future growth will depend on targeted immunomodulatory approaches and improved long-term disease control.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Argenx
• Merida Biosciences
• Biohaven Therapeutics Ltd.
• Immunovant Sciences GmbH
• Sanofi
• Changchun GeneScience Pharmaceutical Co., Ltd.